Financial Performance - Reported sales for Q1 2025 were $614.2 million, down 6.8% year-on-year, and below expectations [3] - Famous Footwear sales decreased by 6.3%, with comparable sales down 4.6% compared to Q1 2024 [4] - Net earnings were $6.9 million, or $0.21 per diluted share, compared to $30.9 million, or $0.88 per diluted share in Q1 2024 [4] - The total net sales for the consolidated segment decreased to $614,221,000 in Q1 2025 from $659,198,000 in Q1 2024, reflecting a decline of approximately 6.8% [18] - For the thirteen weeks ended May 3, 2025, Caleres, Inc. reported net earnings of $6,943,000, a decrease from $30,939,000 for the same period in 2024, resulting in a diluted earnings per share of $0.21 compared to $0.88 [21] - Gross profit was $278.7 million, with a gross margin of 45.4%, down 150 basis points from the previous year [4] - Gross profit for the consolidated segment was $278,694,000, down from $309,095,000 in the prior year, leading to a gross margin of 45.4%, down from 46.9% [18] - Operating earnings for the consolidated segment were $11,584,000, significantly lower than $42,758,000 in the same quarter of 2024, resulting in an operating margin of 1.9% compared to 6.5% [18] - For the thirteen weeks ended May 3, 2025, Caleres, Inc. reported EBITDA of $28,051,000, down from $57,381,000 for the same period in 2024, reflecting a decrease in EBITDA margin from 8.7% to 4.6% [23] - Adjusted net earnings attributable to Caleres, Inc. for the thirteen weeks ended May 3, 2025, were $7,409,000, compared to $30,939,000 in the same period of 2024, with an adjusted diluted earnings per share of $0.22 [22] Expenses and Cost Management - SG&A expenses as a percentage of net sales increased to 43.4%, up 300 basis points year-on-year [4] - The company announced structural cost-cutting actions to reduce SG&A by $15 million on an annualized basis [3] - The company implemented expense reduction initiatives that resulted in a positive impact of $6,103,000 on earnings [19] - The adjusted operating earnings for the Famous Footwear segment were $12,211,000, down from $42,758,000 in the prior year [19] Debt and Borrowings - Borrowings under the asset-based revolving credit facility were $258.5 million, up $67.5 million from Q1 2024 [11] - Caleres, Inc. reported borrowings under the revolving credit agreement of $258,500,000, an increase from $191,000,000 in the previous year [23] - The debt/EBITDA leverage ratio increased to 1.5 from 0.8 year-over-year, indicating a higher level of debt relative to earnings [23] Inventory and Store Operations - Inventory increased by 8.1% compared to Q1 2024 [11] - The company ended the period with 950 company-operated stores, a slight decrease from 954 stores in the previous year [18] Market Outlook - The company has suspended guidance due to market uncertainty [6] - Total charges related to acquisition and integration costs for the Stuart Weitzman brand amounted to $627,000 for the quarter [19] Trailing Twelve Months Performance - For the trailing twelve months ended May 3, 2025, net earnings attributable to Caleres, Inc. were $83,259,000, a decrease from $167,603,000 in the previous year [23] - The trailing twelve months EBITDA was reported at $177,371,000, with a margin of 6.6%, down from $247,157,000 and 8.8% respectively [23] - The adjusted EBITDA for the trailing twelve months was $187,882,000, with an adjusted EBITDA margin of 7.0%, compared to $253,260,000 and 9.0% in the prior year [23]

Financial Results and Projections - Bath & Body Works, Inc. announced anticipated financial results for Q1 2025, with a focus on revenue growth and user engagement metrics[6]. - The financial results and strategic direction will be further detailed in the upcoming earnings call[6]. Leadership Changes - The company appointed Daniel Heaf as the new Chief Executive Officer effective May 16, 2025, succeeding Gina Boswell[8]. - Ms. Boswell's termination will trigger severance payments as per her executive severance agreement, which was previously disclosed[15]. - The press release detailing these changes was issued on May 19, 2025, highlighting the leadership transition[16]. Compensation and Incentives - Mr. Heaf's annual base salary is set at $1,350,000, with a target annual incentive opportunity of 190% of his base salary[10]. - The company plans to provide Mr. Heaf with an annual equity incentive award opportunity valued at $8,000,000 starting in the 2026 fiscal year[10]. - A one-time award of restricted stock units valued at $2,500,000 will be granted to Mr. Heaf, with vesting occurring over three years[10]. Strategic Focus - The company is expected to continue its focus on market expansion and new product development under the new leadership[16]. - The company is committed to maintaining its competitive edge through strategic leadership and operational improvements[16].

Financial Performance - As of March 31, 2025, Immunovant's cash and cash equivalents totaled approximately $714 million, providing runway for announced indications through GD readout expected in 2027[9]. - Research and development expenses for the fourth quarter ended March 31, 2025, were $93.7 million, a 42% increase from $66.1 million for the same period in 2024[10]. - General and administrative expenses for the fourth quarter ended March 31, 2025, were $20.2 million, up from $14.8 million in the prior year, reflecting a 36% increase[11]. - The net loss for the fourth quarter ended March 31, 2025, was $106.4 million ($0.64 per common share), compared to a net loss of $75.3 million ($0.52 per common share) for the same period in 2024, representing a 41% increase in net loss[12]. - For the fiscal year ended March 31, 2025, research and development expenses were $360.9 million, a 70% increase from $212.9 million in the previous fiscal year[13]. - The net loss for the fiscal year ended March 31, 2025, was $413.8 million ($2.73 per common share), compared to a net loss of $259.3 million ($1.88 per common share) for the fiscal year ended March 31, 2024, indicating a 59% increase in net loss[16]. Clinical Development - Immunovant plans to initiate a potentially registrational trial evaluating IMVT-1402 in Sjögren's disease and a second trial in Graves' disease in the summer of 2025[6]. - The company is developing IMVT-1402 in six announced indications, including potentially registrational trials in Graves' disease and difficult-to-treat rheumatoid arthritis[3]. - Immunovant's current management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, with a second potentially registrational study in Graves' disease expected to start in summer 2025[7]. Study Results - Positive results from batoclimab studies showed a 5.6-point improvement in MG-ADL score in the higher dose arm and an 84% responder rate in CIDP patients achieving greater than 70% IgG reduction[4].

Financial Performance - Total sales for Q1 fiscal 2025 were $105.5 million, down 8.6% from $115.5 million in Q1 fiscal 2024, with comparable sales decreasing by 9.4%[5] - Net loss for Q1 fiscal 2025 was $(1.9) million, or $(0.04) per diluted share, compared to net income of $3.8 million, or $0.06 per diluted share in Q1 fiscal 2024[20] - Adjusted EBITDA for Q1 fiscal 2025 was $0.1 million, a significant decrease from $8.2 million in Q1 fiscal 2024[21] - Gross margin rate for Q1 fiscal 2025 was 45.1%, down from 48.2% in Q1 fiscal 2024, primarily due to increased occupancy costs and markdown activity[10] - SG&A expenses as a percentage of sales increased to 45.0% in Q1 fiscal 2025 from 41.1% in Q1 fiscal 2024[13] - Free cash flow before capital expenditures for store development was $(14.5) million for Q1 fiscal 2025, compared to $(4.6) million in Q1 fiscal 2024[50] Cash and Investments - Cash and investments decreased to $29.1 million as of May 3, 2025, from $53.2 million as of May 4, 2024, reflecting $13.6 million in share repurchases[27] - Cash and cash equivalents decreased to $8.1 million as of May 3, 2025, down from $11.9 million on February 1, 2025[46] Inventory Management - Inventory decreased by approximately $5.8 million to $85.5 million as of May 3, 2025, compared to $91.2 million as of May 4, 2024[28] - Inventory levels as of May 3, 2025, were $85.5 million, an increase from $75.5 million on February 1, 2025, but a decrease from $91.2 million a year earlier[46] Future Outlook - The company expects a single-digit decrease in comparable sales for Q2 fiscal 2025, with a return to positive results in the second half of the fiscal year[9] - The company anticipates that the impact of current tariffs on financial results for fiscal 2025 could increase costs by less than $2.0 million, or approximately 40 basis points as a percentage of sales[40] Expansion Plans - FiTMAP sizing technology is currently in 52 DXL retail locations, with plans to expand to 85 stores by the end of fiscal 2025 and up to 200 stores by the end of fiscal 2027[30] - The company plans to open six additional DXL stores during fiscal 2025, with capital expenditures expected to range from $19.0 million to $21.0 million[29] Sales Breakdown - For Q1 fiscal 2025, direct sales were $29.1 million, representing 27.5% of total sales, down from $34.6 million or 30.0% in Q1 fiscal 2024[31] - Total sales for the three months ended May 3, 2025, were $105.5 million, a decrease from $115.5 million in the same period last year[45] - The company reported a net loss of $1.9 million for Q1 fiscal 2025, compared to a net income of $3.8 million in Q1 fiscal 2024[48] - Adjusted EBITDA for Q1 fiscal 2025 was $0.1 million, significantly lower than $8.2 million in Q1 fiscal 2024, resulting in an adjusted EBITDA margin of 0.1% compared to 7.1%[48]

Leadership Changes - The Board of Directors terminated CEO J. Ashley Buchanan for Cause on April 30, 2025, following an investigation into unethical business practices[5][6]. - Interim CEO Michael J. Bender was appointed following Mr. Buchanan's departure, with compensatory arrangements yet to be determined[9][11]. - Mr. Buchanan will forfeit all equity awards and reimburse the company $2,500,000 as part of his termination agreement[7]. - The company emphasized that Mr. Buchanan's termination was not related to its financial performance or reporting[8]. - The Board reduced the number of directors from 12 to 11 after Mr. Buchanan's termination[8]. Financial Performance - Kohl's Corporation announced preliminary expectations for its first quarter 2025 results, with a quarterly earnings conference call scheduled for May 29, 2025[4]. - Forward-looking statements regarding the company's performance are subject to risks and uncertainties that could materially affect actual results[15]. Shareholder Meeting - The annual meeting of shareholders is scheduled for May 14, 2025, where Mr. Buchanan's nomination for election will be withdrawn[8]. - The press release regarding these matters was issued on May 1, 2025[13].

Financial Performance - Comparable sales decreased by 2.6% from the prior-year period, with North America region sales decreasing by 0.5%[5] - Net loss is expected to be $363 million, compared to net income of $8 million in the same period last year[5] - First quarter loss per share is expected to be $3.81, compared to earnings per share of $0.09 in Q1 2024[5] - Non-GAAP net loss is expected to be $6 million, compared to net income of $21 million in the prior-year period[5] - For the first quarter of 2025, the company reported a pre-tax loss of $270 million compared to a pre-tax income of $13 million in the same period of 2024[20] - Adjusted income before income taxes (non-GAAP) for Q1 2025 was $2 million, down from $29 million in Q1 2024, reflecting a significant decline[20] - The net loss for Q1 2025 was $363 million, compared to a net income of $8 million in Q1 2024[20] - Adjusted net loss income (non-GAAP) for Q1 2025 was $6 million, a decrease from $21 million in Q1 2024[20] - Diluted loss per share for Q1 2025 was $3.81, compared to diluted earnings per share of $0.09 in Q1 2024[20] - Adjusted diluted loss earnings per share (non-GAAP) for Q1 2025 was $(0.07), down from $0.22 in Q1 2024[20] Impairment Charges - Non-cash impairment charges totaling $276 million are expected, primarily related to a tradename and goodwill impairment[5] - The company recorded impairment charges of $140 million for the WSS tradename and $110 million for goodwill in Q1 2025 due to a decline in stock price and market capitalization[21] - A valuation allowance of $117 million was recorded on deferred tax assets related to net operating loss carryforwards in Q1 2025, indicating a reduced likelihood of utilizing these assets[22] Merger Agreement - Foot Locker and DICK'S Sporting Goods announced a merger agreement with an equity value of approximately $2.4 billion and an enterprise value of approximately $2.5 billion[6] - Shareholders will have the option to receive either $24.00 in cash or 0.1168 shares of DICK'S common stock for each share of Foot Locker common stock[6] - The transaction is subject to shareholder approval and is expected to close in the second half of 2025[7] Strategic Focus - The company is focusing on enhancing in-store experiences and digital offerings, including new mobile apps for Champs Sports and Kids Foot Locker[2] - The company closed all stores in South Korea, Denmark, Norway, and Sweden as part of its strategy to improve international operations[21] - The company reported a $5 million gain on the sale of its Greece and Romania businesses in Q1 2025[22] Reporting Schedule - Foot Locker plans to report full financial results for Q1 2025 on May 29, 2025, but will not hold a conference call due to the pending transaction[8]

Dividend Policy and Restrictions - The company has not declared or paid any dividends on its common stock and intends to retain all available funds for operations and growth[26]. - The company's ability to pay dividends is subject to PRC legal restrictions, which permit payments only from accumulated after-tax profits[28]. - The ability to pay dividends is limited to the registered capital amount of the WFOE, as determined by Chinese accounting standards[35]. - The Chinese government imposes controls on the conversion of RMB into foreign currencies, potentially complicating the remittance of dividends[35]. - The company relies on payments from the VIE to the WFOE to facilitate dividend payments to shareholders[31]. - The ability to pay dividends is subject to Chinese taxes, including a 6% VAT and 25% enterprise income tax, which may restrict cash flow[31]. - Current Chinese regulations allow the WFOE to pay dividends only out of its registered capital, which may limit the Company's ability to distribute profits[35]. - The company’s WFOE must allocate at least 10% of annual after-tax profits to a statutory general reserve fund until it reaches 50% of registered capital[28]. Regulatory Compliance and Risks - The company has not received any inquiries or sanctions from the CSRC regarding the Overseas Listing Trial Measures as of the report date[23]. - The Overseas Listing Trial Measures require domestic companies to file with the CSRC for overseas offerings if certain conditions are met, potentially impacting the company's operations[20]. - The company faces uncertainties regarding the interpretation and application of Chinese laws and regulations, which could materially affect its operations[19]. - The company faces risks related to the interpretation of Chinese laws and regulations regarding the VIE structure, which could materially affect operations[18]. - The PCAOB determined it could inspect registered public accounting firms in mainland China and Hong Kong, affecting the company's compliance status under the HFCAA[36]. - As of the latest report, the company is not a Commission Identified Issuer under the HFCAA, reducing the risk of delisting from Nasdaq[36]. - The enactment of the HFCAA could still cause investor uncertainty and negatively impact the market price of the company's common stock[37]. - The Overseas Listing Trial Measures require domestic companies to comply with filing procedures for overseas offerings, with penalties for non-compliance ranging from RMB1,000,000 to RMB10,000,000[20]. VIE Structure and Financial Implications - The company relies on payments from its VIE to its WFOE under the VIE Agreements for cash requirements, including dividends[25]. - The VIE is obligated to make payments to the WFOE, but such payments are subject to Chinese taxes, including a 6% VAT and 25% enterprise income tax[25]. - The VIE is obligated to make payments to the WFOE, which may be restricted by Chinese taxes including a 6% VAT and 25% enterprise income tax[31]. - The company relies on payments from the VIE to the WFOE for cash requirements, which may be limited by various regulatory restrictions[31]. Cybersecurity and Investigations - The company has not been involved in any cybersecurity investigations by Chinese regulatory authorities as of the report date[19]. - The company has not been involved in any cybersecurity investigations by Chinese regulatory authorities as of the report date[19].

Financial Performance - Comparable sales decreased by 0.7% in Q1 FY26 compared to a decline of 6.1% in Q1 FY25[2] - Total revenue for Q1 FY26 was $8.767 billion, down from $8.847 billion in Q1 FY25, representing a decrease of 0.9%[2][4] - Adjusted diluted EPS for Q1 FY26 was $1.15, compared to $1.20 in Q1 FY25[2] - Net earnings for the three months ended May 3, 2025, were $202 million, down 17.9% from $246 million in the same period last year[27] - Domestic segment revenue was $8,127 million, a slight decrease of 0.9% compared to $8,203 million in the prior year[30] - Adjusted operating income remained stable at $333 million, with an adjusted operating income margin of 3.8%[34] Guidance and Expectations - The company expects FY26 adjusted diluted EPS to be in the range of $6.15 to $6.30[1] - For Q2 FY26, the company anticipates comparable sales to be slightly down and adjusted operating income rate to be approximately 3.6%[4] - The updated FY26 guidance includes revenue expectations of $41.1 billion to $41.9 billion, with comparable sales growth projected between -1.0% to 1.0%[10] Revenue Sources - Domestic online revenue increased by 2.1% to $2.58 billion, accounting for 31.7% of total domestic revenue[5] - Comparable sales in the domestic segment decreased by 0.7%, while comparable online sales increased by 2.1%[30] Costs and Charges - The company incurred $109 million in restructuring charges in Q1 FY26, primarily related to the Best Buy Health business[12] - The restructuring charges for the quarter were $109 million, significantly higher than $15 million in the same period last year[35] Tax and Assets - The effective tax rate for Q1 FY26 was 8.6%, significantly lower than 24.7% in Q1 FY25, influenced by restructuring charges[13] - The effective tax rate for the quarter was 8.6%, compared to 24.7% in the same quarter last year[34] - Total assets decreased to $14,128 million from $14,752 million year-over-year, a decline of 4.2%[25] Cash Flow and Stock Repurchase - The company reported a total cash provided by operating activities of $34 million, significantly down from $156 million in the previous year[27] - Cash, cash equivalents, and restricted cash at the end of the period were $1,435 million, down from $1,527 million year-over-year[27] - The company repurchased $100 million of common stock during the quarter, up from $50 million in the prior year[27] Profitability - The domestic gross profit rate improved to 23.5% from 23.4% in the previous year, driven by better performance in services[6]

Exhibit 99.1 BUILD-A-BEAR WORKSHOP REPORTS RECORD-BREAKING FIRST QUARTER FISCAL 2025 RESULTS First Quarter Fiscal 2025 Results (13 weeks ended May 3, 2025, compared to the 13 weeks ended May 4, 2024) ● Total revenues were a first-quarter record $128.4 million, an increase of 11.9%, pre-tax income was a first-quarter record $19.6 million, an increase of 30.6%, and diluted earnings per share was a first-quarter record $1.17, an increase of 42.7% ● For the first quarter of 2025, the Company returned $7.1 milli ...

FOR IMMEDIATE RELEASE SpartanNash Announces First Quarter Fiscal 2025 Results Sales Growth of 3.7%, Included a 1.6% Increase in Retail Comparable Store Sales Reaffirms Fiscal 2025 Guidance GRAND RAPIDS, Mich. – May 29, 2025 – Food solutions company SpartanNash® (the "Company") (Nasdaq: SPTN) today reported financial results for its 16-week first quarter ended April 19, 2025. "We continue to execute on our strategic initiatives and deliver on our commitments. SpartanNash hit the ground running in 2025, posti ...